The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today
approved a securities note, a registration document and a summary (together
referred to as the "Prospectus"), which prepares for potential future share
issues and conversions of bonds under the bond terms and the Investment
Agreement with Atlas Special Opportunities LLC and Atlas Capital Markets LLC.
The Prospectus is available on the Company's
website: https://www.circio.com/en/section/investors/prospectus/
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.circio.com%2Fen%2Fsection%2Finvestors%2Fprospectus%2F&data=05%7C02%7Cmats.hermansen%40circio.com%7C5b2e58c7684c4d70a6ac08ddfb51ad30%7C66b0661a3ec348a8a9665b0cce82b3fe%7C0%7C0%7C638943050431341713%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=9SJuyOMF64W0LRHXWdxnIB0L95IPhXj3qSImT75gnGo%3D&reserved=0)
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.
In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.